EVGN
EVGN
NASDAQ · Biotechnology

Evogene Ltd

$0.82
0.00 (-0.18%)
Financial Highlights (FY 2026)
Revenue
4.18M
Net Income
-9,212,717
Gross Margin
50.3%
Profit Margin
-220.2%
Rev Growth
+31.9%
D/E Ratio
0.95
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 50.3% 50.3% 51.3% 51.3%
Operating Margin -363.3% -327.0% 25.9% 22.8%
Profit Margin -220.2% -209.2% 25.9% 19.0%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 4.18M 3.17M 3.80M 4.24M
Gross Profit 2.10M 1.60M 1.95M 2.18M
Operating Income -15,196,612 -10,370,754 984.3K 966.3K
Net Income -9,212,717 -6,287,113 985.2K 805.1K
Gross Margin 50.3% 50.3% 51.3% 51.3%
Operating Margin -363.3% -327.0% 25.9% 22.8%
Profit Margin -220.2% -209.2% 25.9% 19.0%
Rev Growth +31.9% +31.9% +24.5% -6.6%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.75M 1.75M 3.82M 3.96M
Total Equity 1.83M 1.83M 3.81M 3.70M
D/E Ratio 0.95 0.95 1.00 1.07
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -13,995,191 -10,081,461 1.34M 1.32M
Free Cash Flow 1.13M 1.05M